(Reuters) -The U.S. Food and Drug Administration is probing the death of a patient who developed harmful antibodies after taking Takeda Pharmaceuticals' blood disorder therapy, the health regulator said on Friday.
The pediatric patient died about 10 months after starting Takeda's drug Adzynma as a preventive therapy, the agency said.
The child had congenital thrombotic thrombocytopenic purpura (cTTP), an inherited condition that causes blood clots in small vessels and can lead to organ damage.
The FDA said the child developed antibodies that blocked the activity of ADAMTS13, an enzyme critical for blood clotting.
Takeda did not immediately respond to Reuters request for comment.
Adzynma, approved in 2023 as the first therapy for cTTP, replaces the ADAMTS13 protein to help prevent dangerous blood clots.
The agency added it has received multiple postmarketing reports of patients developing neutralizing antibodies to ADAMTS13 after treatment with Adzynma.
(Reporting by Kamal Choudhury in Bengaluru; Editing by Vijay Kishore)
LATEST POSTS
- 1
Why doing good also makes us feel good, during the holidays and beyond - 2Iran war fuels fears of new inflation wave among German consumers
- 3Scientist turns people’s mental images into text using ‘mind-captioning’ technology
- 4Mosquitoes carrying malaria are evolving more quickly than insecticides can kill them – researchers pinpoint how
- 5The most effective method to Amplify Your Opportunity for growth in a Web-based Degree Program
- Upgrading the Healthy benefit of Your Local Vegetables
- Accor signs agreement to transform El Gouna resort as Sofitel
- Social Skylines d: A Survey of \Inside and out Social Experiences\ Language Learning Book
- Gov’t approves millions for border cities in North under Hezbollah fire
- What will happen if Artemis 2 astronauts get hit by a solar storm during NASA's ambitious moon mission?
- 5 State of the art Advancements in Computer generated Simulation
- Thousands of New York City nurses set to strike Monday if deal isn't reached with hospitals
- Bitcoin momentum builds in Abu Dhabi as global interest surges
- Monetary Freedom Guide: Plan Your Future
